L&C Bio plans to launch MegaAdipoECM, an injectable skin booster made from donated human fat, targeting 'Ozempic face' and offering a biological alternative to silicone implants, set to launch in late 2027.
Elcella and Calocurb, natural supplements developed in the UK and NZ, respectively, aim to mimic synthetic diabetes medications' weight-loss effects by stimulating 'fullness hormones' GLP-1 and PYY, with promising but limited human trial results.
Growing demand for mini fridges for beauty products and GLP-1 medication is reshaping homes, driven by the wellness industry and weight-loss drugs. This trend spans luxury to budget markets, despite dermatological skepticism for most skincare products.
The "proteinmaxxing" trend and GLP-1 weight-loss medications are driving up demand for whey protein, a vital ingredient in infant formula. This has led to a 4.8% increase in UK formula prices, raising concerns about affordability for families and prompting calls for government-imposed price or profit caps.
US retail giants like Walmart, Costco, CVS, and Amazon are leveraging direct-to-consumer GLP-1 weight-loss drug programs to acquire long-term customer relationships, as employers increasingly drop coverage. This strategy aims to drive loyalty and cross-selling opportunities.
Galderma CEO Flemming Ørnskov stated that the increased use of weight-loss drugs like Ozempic and Wegovy presents a "significant opportunity" for the aesthetics company, particularly in mitigating facial sagging. The company reported nearly 25% sales growth, with U.S. growth outpacing other regions at 32%.
Novo Nordisk is suing Eli Lilly, alleging "false and misleading" advertisements for its weight-loss and anti-diabetes treatments, Zepbound and Mounjaro. Novo Nordisk claims Lilly used outdated studies comparing its highest doses against lower doses of Novo Nordisk's drugs, creating a deceptive impression of superiority. Eli Lilly defends its ads, citing the Surmount-5 trial as the only direct comparison.
Novo Nordisk has filed a lawsuit in the US against Eli Lilly, accusing its rival of false advertising regarding the superiority of its weight-loss drugs, Mounjaro and Zepbound. Novo Nordisk claims Eli Lilly compared lower doses of Novo Nordisk's drugs with higher doses of its own, omitting newer options.
Two US biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, are testing experimental GLP-1 weight-loss treatments for overweight cats, aiming to bring the blockbuster drug class into pet medicine amidst a growing pet obesity problem and increasing owner spending on pet health.
Weight-loss medications like Wegovy and Mounjaro are significantly altering UK consumer spending. Research indicates users spend less on groceries and eating out, shifting purchases towards healthier options and products that mitigate side effects, though spending patterns may revert upon cessation.
Nithin Kamath questions India's slow uptake of affordable GLP-1 weight-loss drugs despite rising obesity, citing challenges like long-term adherence and physician conservatism, prompting a cautionary response from Kiran Mazumdar-Shaw emphasizing diet and exercise for non-diabetic, non-obese individuals.
Despite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Zerodha co-founder Nithin Kamath attributes this to patient retention issues with weekly injections and conservative doctor prescribing habits. Oral alternatives may boost uptake, suggesting convenience, not price, will drive future acceptance.
UPS is investing $48 million in 27 temperature-controlled facilities globally to meet the rising demand for GLP-1 weight-loss drugs and other sensitive medications, ensuring they remain within required temperature ranges for patient use.
Demand for weight-loss drugs, cosmetic procedures, and wellness treatments is driving out-of-pocket healthcare expenses in India. Most of these, like Botox and anti-obesity drugs, are not covered by standard health insurance unless medically necessary, experts advise understanding policy exclusions and avoiding EMIs for elective treatments.
Demand for weight-loss drugs, cosmetic procedures, and wellness treatments is driving out-of-pocket healthcare spending in India. Most of these interventions, like Botox and anti-obesity drugs, are not covered by standard health insurance unless medically necessary. Experts advise reviewing policy exclusions and avoiding EMIs for elective treatments.
GLP-1 weight-loss drug users in Great Britain are saving an average of £418 annually on groceries, with household use nearly tripling in two years to 1.9 million adults. The drugs are impacting food consumption and forcing retailers to adapt.
Canada has become the first G7 nation to approve generic semaglutide injections, making GLP-1 drugs more accessible and affordable. This move by Novo Nordisk follows similar approvals in India and has already led to price reductions for brand-name medications.
Canada has become the first G7 nation to approve generic semaglutide injections, making GLP-1 drugs more accessible and affordable. This move by Novo Nordisk follows similar approvals in India and may pressure US prices, though generics are not expected there until 2032.
Research indicates that using weight-loss drugs like Mounjaro, Wegovy, and Ozempic for at least three years could significantly reduce the need for knee replacement surgeries, potentially preventing thousands of procedures annually in the US and UK.
New studies presented at a major oncology conference suggest GLP-1 weight-loss drugs could reduce cancer risk by 30%. Research indicates they may lower the likelihood of developing breast cancer, decrease mortality risk in breast cancer patients, and reduce the spread of various cancers.
Experts suggest the rise of weight-loss drugs like Wegovy could influence future art, potentially popularizing a "GLP-1 face" characterized by rapid fat loss, similar to past aesthetic trends. This shift contrasts with historical art that often celebrated fuller figures.
A new wave of female pop stars, including Slayyyter, Kesha, and Tove Lo, are embracing a "trash-pop" aesthetic characterized by hedonistic lyrics, anarchic sexuality, and a "white trash" sensibility. This trend, influenced by early 00s electroclash and reality TV culture, represents a rejection of feminine respectability and a cathartic expression of anger and frustration.
The rising popularity of GLP-1 weight-loss drugs is driving a surge in demand for hair-care products as users report temporary hair loss. Beauty companies are now innovating and marketing specific treatments to address this growing side effect.
